Antiphospholipid Syndrome: Clinical Trials

14 trials for Antiphospholipid Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 recruiting, 2 withdrawn, 1 active not recruiting, 1 enrolling by invitation. 14 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 114Recruiting 9, Withdrawn 2, Active not recruiting 1, Enrolling by invitation 1, Not yet recruiting 1
Phase 23Recruiting 2, Withdrawn 1

Follow Antiphospholipid Syndrome: new trials by email Literature Review of Antiphospholipid Syndrome trials Research Report on Antiphospholipid Syndrome

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase I, Dose Escalation, Open-label, Multicenter Study of EA5 Injection in Adults With APS and Recurrent Thrombosis
EA5 - Antiphospholipid Syndrome (APS), Thrombosis
Phase 1Active not recruitingShanghai Lanyi Therapeutics Co., Ltd.122026-05-252026-06-08
YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
YTS109 cell - Systemic Lupus Erythematosus (SLE), Diffuse Systemic Sclerosis
Phase 1Not yet recruitingChildren's Hospital of Fudan University122026-03-012026-02-27
An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
YTS109 cell - Systemic Lupus Erythematosus, Lupus Nephritis (LN)
Phase 1RecruitingChina Immunotech (Beijing) Biotechnology Co., Ltd.182025-11-242026-03-04
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
YTS109 cell - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis
Phase 1RecruitingChina Immunotech (Beijing) Biotechnology Co., Ltd.182025-11-132026-03-02
A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases
YTS109 cell - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Phase 1RecruitingChina Immunotech (Beijing) Biotechnology Co., Ltd.182025-08-132026-10-21
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
YTS109 cell - Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Phase 1RecruitingChina Immunotech (Beijing) Biotechnology Co., Ltd.182025-08-042026-10-21
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
anti-CD19 CAR T cell therapy - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Phase 1 / Phase 2RecruitingPeking University Third Hospital92025-07-012026-09-22
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
YTS109 cell - Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
Phase 1RecruitingChina Immunotech (Beijing) Biotechnology Co., Ltd.122025-05-192026-10-21
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1Enrolling by invitationChugai Pharmaceutical1442024-12-092026-07-17
Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
HBI0101 CART - Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
Phase 1RecruitingPolina Stepensky1202024-09-012026-05-06
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP)
Phase 1RecruitingChugai Pharmaceutical1442024-08-192026-07-22
Daratumumab in Primary Antiphospholipid Syndrome
Daratumumab - Autoimmune Disorders
Phase 1 / Phase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)222023-05-262026-10-21
Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss
Low dose steroids - Antiphospholipid Syndrome
Phase 1 / Phase 2WithdrawnImperial College London2005-10-012024-02-26
Hematopoietic Stem Cell Transplantation in Patients With Antiphospholipid Syndrome
Stem Cell Transplantation - ANTIPHOSPHOLIPID SYNDROME
Phase 1WithdrawnRichard Burt, MD2005-08-012012-04-11

Narrower conditions

Myositis (8)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (7)  ·  Lupus Erythematosus, Systemic (7)  ·  Scleroderma, Systemic (5)  ·  Sjogren's Syndrome (4)  ·  Autoimmune Diseases (3)  ·  Lupus Nephritis (3)  ·  Arthritis, Rheumatoid (2)  ·  Behcet Syndrome (2)  ·  Dermatomyositis (2)  ·  Pemphigoid, Bullous (2)  ·  Purpura, Thrombocytopenic, Idiopathic (2)  ·  Recurrence (2)  ·  Immunoglobulin G4-Related Disease (1)

Broader conditions

Immune System Diseases (14)  ·  Autoimmune Diseases (11)  ·  Cardiovascular Diseases (10)  ·  Connective Tissue Diseases (10)  ·  Muscular Diseases (10)  ·  Musculoskeletal Diseases (10)  ·  Nervous System Diseases (10)  ·  Neuromuscular Diseases (10)  ·  Skin Diseases (10)  ·  Skin and Connective Tissue Diseases (10)  ·  Vascular Diseases (10)  ·  Skin Diseases, Vascular (9)  ·  Vasculitis (9)  ·  Eye Diseases (7)  ·  Systemic Vasculitis (7)

Interventions

Stem Cell Transplantation (1)  ·  Steroids (1)  ·  daratumumab (1)

Sponsors

China Immunotech (Beijing) Biotechnology Co., Ltd. (5)  ·  Chugai Pharmaceutical (2)  ·  Children's Hospital of Fudan University (1)  ·  Imperial College London (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Peking University Third Hospital (1)  ·  Polina Stepensky (1)  ·  Richard Burt, MD (1)  ·  Shanghai Lanyi Therapeutics Co., Ltd. (1)

Countries

China (8)  ·  United States (3)  ·  Australia (2)  ·  Austria (2)  ·  Bulgaria (2)  ·  Canada (2)  ·  Croatia (2)  ·  Czechia (2)  ·  France (2)  ·  Germany (2)  ·  Hungary (2)  ·  Italy (2)  ·  Japan (2)  ·  Netherlands (2)  ·  Norway (2)

Top investigators

Doruk Erkan, M.D., M.P.H. (1)  ·  Jason Knight, M.D., Ph.D. (1)  ·  Raj Rai, MRCOG (1)  ·  Richard Burt, MD (1)

Results publications

PMID 32358837

NIH funding

2005 (1)